Find relevant news articles from other European projects, below:
Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:
The promise of CAR-T cell therapy
Innovative Medicine Initiative (IMI) is a EU public-private partnership funding health research and innovation. Complex therapies like CAR-T cells pose questions no drug developer can answer on thei own.
Death receptor pathway drives resistance to CAR T-cell therapy
Some cancer cells refuse to die, even in the face of powerful cellular immunotherapies like CAR T-cell therapy, and new research from the Abramson Cancer Center of the University of Pennsylvania is shedding light on why. Read the full article here
Management of Toxicities from Immunotherapy: ESMO Clinial Guidelines
Immunotherapy is an essential component of cancer care and expands the treatment possibilities for patients. Immune checkpoint inhibitors are among the most promising drugs but are associated with toxicities. The most frequently occurring ones affect skin, colon, endocrine organs, liver and lungs.
Phase III CASSIOPEIA Impacts Treatment Decisions in Patients With Multiple Myelo...
Sonneveld says that not only high-risk patients but all those who are transplant-eligible and newly diagnosed may potentially have a new standard of care in the future.
ELARA: A phase II, single-arm, multicenter, open-label trial investigating the e...
Novartis today announced positive results from the Phase II ELARA trial of Kymriah® (tisagenlecleucel) in patients with relapsed or refractory (r/r) follicular lymphoma (FL).